@article{3003180,
    title = "Hypogammaglobulinemia in rheumatoid arthritis patients treated with rituximab: should we switch biologics? Comment on the article by Fraenkel et al",
    author = "Evangelatos, G. and Moschopoulou, M. and Iliopoulos, A. and Fragoulis, G.E.",
    journal = "Arthritis and Rheumatology",
    year = "2022",
    volume = "74",
    number = "1",
    pages = "174-175",
    publisher = "John Wiley and Sons Inc",
    issn = "2326-5191, 2326-5205",
    doi = "10.1002/art.41938",
    keywords = "antibiotic agent;  C reactive protein;  disease modifying antirheumatic drug;  immunoglobulin A;  immunoglobulin G;  immunoglobulin M;  rituximab;  antirheumatic agent;  biological product;  rituximab, antibiotic therapy;  DAS28;  disease activity;  drug substitution;  drug withdrawal;  follow up;  human;  immunoglobulin blood level;  immunoglobulin deficiency;  immunotherapy;  Letter;  rheumatoid arthritis;  risk factor;  treatment switching;  agammaglobulinemia, Agammaglobulinemia;  Antirheumatic Agents;  Arthritis, Rheumatoid;  Biological Products;  Humans;  Rituximab"
}